CBF5 Antibody

CBF5 Protein Overview

CBF5 (Cbf5 in archaea, dyskerin in humans) is a catalytic subunit of H/ACA ribonucleoprotein complexes responsible for pseudouridylation, a post-transcriptional RNA modification critical for ribosome biogenesis and telomerase function. Key features include:

• Structural domains: A catalytic TruB-like domain and a PUA domain that binds ACA motifs in guide RNAs .

• Functional residues: Conserved histidines (e.g., H31 and H48 in Haloferax volcanii Cbf5) are essential for RNA-guided pseudouridylation .

• Disease relevance: Mutations in its human homolog, dyskerin (DKC1), cause dyskeratosis congenita .

Antibody Characterization Principles

While no specific CBF5 antibody is detailed in the search results, general antibody validation guidelines from recent research apply:

Five Pillars of Antibody Validation5

Challenges in CBF5 Antibody Development

• Low abundance: CBF5 is an essential nucleolar protein with potential low expression levels, complicating detection .

• Conserved epitopes: Structural similarities between CBF5 and TruB (a related pseudouridine synthase) may lead to cross-reactivity .

• Mutation sensitivity: The CBF5 L52P mutation in yeast reduces pseudouridylation activity , which could alter antibody binding if epitopes are conformation-dependent.

Antibody Applications in CBF5 Research

Hypothetical applications based on CBF5’s role:

• Localization studies: Track CBF5 in nucleoli using immunofluorescence .

• Functional assays: Monitor CBF5-RNA interactions via co-immunoprecipitation .

• Disease models: Detect dyskerin (human CBF5) mutations in dyskeratosis congenita patient cells .

Key Research Findings

• Cbf5-guide RNA interaction: The PUA domain of Cbf5 specifically recognizes ACA trinucleotides in guide RNAs, a feature absent in TruB .

• Histidine roles: H31 (Cbf5-specific) is critical for RNA-guided activity, while H48 (shared with TruB) is dispensable .

• Mutation effects: The S. cerevisiae CBF5 initiator codon mutation (AUG→AUU) reduces protein levels and disrupts tRNA silencing .

Future Directions

• Antibody engineering: Develop recombinant antibodies targeting Cbf5’s ACA-binding PUA domain .

• Quantitative assays: Use CBF5 antibodies in single-molecule studies to resolve its dynamics in RNPs .